Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 30, Issue 4, pp 272–276 | Cite as

Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas

  • David C. Smith
  • Nicholas A. Vick
  • Donald L. Trump
  • Henry S. Friedman
  • Allan H. Friedman
  • Joseph Purvis
  • Al Gauspari
  • S. Clifford ScholdJr.
Original Articles BCNU, 6-Mercaptopurine, Anaplastic Glioma

Summary

On the basis of response rates of up to 50%, BCNU [1,3-bis(2-chloroethyl)-1-nitrosourea] is the primary drug used in the chemotherapy of anaplastic gliomas. Preclinical data obtained in several experimental systems show that the cytotoxicity of chloroethylnitrosoureas can be increased by the concomitant use of thiopurines. In this phase I trial, patients with anaplastic gliomas received standard-dose BCNU (200 mg/m2×1) in combination with escalating doses of intravenous 6-mercaptopurine (200, 350, 500, and 750 mg/m2 daily×3), with BCNU being given on day 3 to maximize the effect of the drugs on cellular DNA. No increase in hematologic toxicity was demonstrated as the dose of 6-mercaptopurine was increased. Responses and stabilization of disease were observed in several patients. Due to the safety of and the evidence of activity found for this regimen in the present trial, 750 mg/m2 6-mercaptopurine has been incorporated into subsequent studies.

Keywords

Cancer Research Experimental System Hematologic Toxicity BCNU Preclinical Data 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aronin PA, Mahaley MS, Rudnick SA, Dudka LA, Donohue JF, Selker RG, Moore P (1980) Prediction of BNCU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. N Engl J Med 303: 183Google Scholar
  2. 2.
    Bodell WJ, Morgan WF, Rasmussen J, Williams ME, Deen DF (1985) Potentiation of 1,3-bis(chloroethyl)-18-nitrosourea (BCNU) cytotoxicity in 9L cells by pretreatment with 6-thioguanine. Biochem Pharmacol 34: 515Google Scholar
  3. 3.
    Chang CH, Horton J, Schoenfeld D, Salazar O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management gliomas. Cancer 52: 997Google Scholar
  4. 4.
    Duttera MJ, Carolla RL, Gallelli JF, Gullion DS, Keim DE, Henderson ES (1972) Hematuria and crystalluria after high-dose 6-mercap-topurine administration. N Engl J Med 287: 292Google Scholar
  5. 5.
    Fujimoto S, Ogawa M (1980) Lethal toxicity and myelotoxicity to mice of the combination of 6-thioguanine and 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride. Jpn J Cancer Res 71: 667Google Scholar
  6. 6.
    Fujimoto S, Inagaki J, Horikoshi N, Hoshino A (1977) Combination chemotherapy of 6-mercaptopurine with various antitumor agents against murine leukemia L-1210. Jpn J Cancer Res 68: 543Google Scholar
  7. 7.
    Fujimoto S, Ogawa M, Hoshino A (1980) Potentiation of therapeutic effects of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride by 6-thioguanine in mouse tumor systems: comparison with other antimetabolites. Jpn J Cancer Res 71: 60Google Scholar
  8. 8.
    Fujimoto S, Ogawa M, Sakurai Y (1982) Hypothetical mechanism of therapeutic synergism of 6-thioguanine and 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride. Cancer Res 42: 4079Google Scholar
  9. 9.
    Kovach JS, Rubin J, Creagan ET, Schutt AJ, Kvols LK, Svingen PA, Hu TC (1986) Phase I trial of parenteral 6-thioguanine given on 5 consecutive days. Cancer Res 46: 5959Google Scholar
  10. 10.
    Levin VA, Phuphanich S, Liu HC, Da Silva V, Murovic J, Choucair A, Chamberlain M, Berger M, Seager M, Davis RL, Silver P, Gutin PH, Wilson CB (1986) Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. Cancer Treat Rep 70: 1271Google Scholar
  11. 11.
    Rodriguez LA, Prados M, Fulton D, Edwards MSB, Silver P, Levin V (1988) Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. Neurosurgery 22: 691Google Scholar
  12. 12.
    Schabel FM Jr, Laster WR Jr, Trader M, Corbett TH, Griswold DP (1981) Combination chemotherapy with nitrosoureas plus other anticancer drugs against animal tumors. In: (eds), Nitrosoureas: current status and new developments. Academic Press, New York, p 9Google Scholar
  13. 13.
    Schold SC, Friedman HS, Elion GB, Mitra S, Bigner DD (1987) Therapeutic synergy of thiopurines and alkylating drugs in a human glioma xenograft. Proc Am Assoc Cancer Res 28: 416Google Scholar
  14. 14.
    Selker RG, Jacobs SA, Moore PB (1980) BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea)-induced pulmonary fibrosis. Neurosurgery 7: 560Google Scholar
  15. 15.
    Walker MD, Hurwitz BS (1970) BCNU 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC-409962) in the treatment of malignant brain tumor — a preliminary report. Cancer Chemother Rep 54: 263Google Scholar
  16. 16.
    Walker MD, Alexander E, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49: 333Google Scholar
  17. 17.
    Walker MD, Green SB, Byar DP, Alexander E, Batzdorf J, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Owens G, Ransohoff J, Robertson JT, Shapiro WR, Smith KR, Wilson CB, Strike TA (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323Google Scholar
  18. 18.
    Wang AM, Elion GB, Friedman HS, Bodell WJ, Bigner DD, Schold SC (1991) Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts. Cancer Chemother Pharmacol 27: 278Google Scholar
  19. 19.
    Wilson CB, Boldrey EB, Enot KJ (1970) 1,3-bis(2-Chloroethyl)-1-nitrosourea (NSC-409962) in the treatment of brain tumors. Cancer Chemother Rep 54: 273Google Scholar
  20. 20.
    Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner B, Poplack DG (1983) Variable bioavailability of oral mercaptopurine: is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 308: 1005Google Scholar
  21. 21.
    Zimm S, Ettinger LJ, Holcenberg JS, Kamen BA, Vietti TJ, Belasco J, Cogliano-Shutta N, Balis F, Lavi LE, Collins JM, Poplack DG (1985) Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. Cancer Res 45: 1869Google Scholar

Copyright information

© Springer-Velag 1992

Authors and Affiliations

  • David C. Smith
    • 1
  • Nicholas A. Vick
    • 5
  • Donald L. Trump
    • 1
    • 7
  • Henry S. Friedman
    • 3
    • 7
  • Allan H. Friedman
    • 4
  • Joseph Purvis
    • 6
  • Al Gauspari
    • 6
  • S. Clifford ScholdJr.
    • 2
    • 7
  1. 1.Division of Hematology/Oncology Evanston HospitalMcGaw Medical Center of Northwestern UniversityDurhamUSA
  2. 2.Division of Neurology Evanston HospitalMcGaw Medical Center of Northwestern UniversityDurhamUSA
  3. 3.Division of Department of Medicine, Division of Hematology/Oncology, Department of Pediatrics Evanston HospitalMcGaw Medical Center of Northwestern UniversityDurhamUSA
  4. 4.Division of Neurosurgery, Department of Surgery, Evanston HospitalMcGaw Medical Center of Noothwestern UniversityDurhamUSA
  5. 5.Duke University Medical Center, the Division of Neurology, Evanston HospitalMcGaw Medical Center of Northwestern UniversityDurhamUSA
  6. 6.Burroughs Wellcome CompanyDurhamUSA
  7. 7.Duke Comprehensive Cancer CenterDurhamUSA

Personalised recommendations